Beam Therapeutics Inc. (BEAM) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US07373V1052
Beam Therapeutics Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 139.74 m USD |
| Operating income | -383.69 m USD |
| EBIT | -79.99 m USD |
| Net income | -79.99 m USD |
| Diluted EPS – continuing operations | -0.81 USD |
Full history since 2017, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Beam Therapeutics Inc.
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
More stocks
- Beijing Haohua Energy Resource Co Ltd (601101.SS)
- Tiger Brands Ltd (TBS.JO)
- Jizhong Energy Resources Co Ltd (000937.SZ)
- Titan America SA (TTAM)
- Stock Yards Bancorp, Inc. (SYBT)
- Eternal Materials Co Ltd (1717.TW)
- Four Corners Property Trust, Inc. (FCPT)
- Hong Ri Da Technology Co. Ltd. A (301285.SZ)
- Tecnicas Reunidas SA (TRE.MC)
- Wallenstam AB (WALL B.ST)
- TransMedics Group, Inc. (TMDX)
- Cosan SA ADR (CSAN)
Not investment advice. All data without warranty, price as of 21.10.2026. Details in the risk notice.